Vanguard Group Inc Arcellx, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Arcellx, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,944,885 shares of ACLX stock, worth $305 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,944,885
Previous 3,985,156
1.01%
Holding current value
$305 Million
Previous $261 Million
0.63%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ACLX
# of Institutions
219Shares Held
49.1MCall Options Held
245KPut Options Held
885K-
Paradigm Biocapital Advisors LP New York, NY4.65MShares$360 Million14.29% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$290 Million20.45% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$272 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$235 Million4.37% of portfolio
-
Vestal Point Capital, LP New York, NY2.75MShares$213 Million9.53% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.39B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...